Duloxetine hydrochloride + placebo
ApprovedCompleted 1 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Urinary Incontinence, Stress
Conditions
Urinary Incontinence, Stress
Trial Timeline
Oct 1, 2005 → Jan 1, 2007
NCT ID
NCT00244296About Duloxetine hydrochloride + placebo
Duloxetine hydrochloride + placebo is a approved stage product being developed by Eli Lilly for Urinary Incontinence, Stress. The current trial status is completed. This product is registered under clinical trial identifier NCT00244296. Target conditions include Urinary Incontinence, Stress.
What happened to similar drugs?
20 of 20 similar drugs in Urinary Incontinence, Stress were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (11)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00673452 | Approved | Completed |
| NCT00536471 | Approved | Completed |
| NCT00422162 | Approved | Completed |
| NCT00408993 | Phase 3 | Completed |
| NCT00406848 | Approved | Completed |
| NCT00244296 | Approved | Completed |
| NCT00191919 | Phase 3 | Completed |
| NCT00122863 | Phase 3 | Completed |
| NCT00122824 | Phase 3 | Completed |
| NCT00190996 | Phase 3 | Completed |
| NCT00058968 | Phase 3 | Completed |
Competing Products
20 competing products in Urinary Incontinence, Stress